Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia - Related Studies

Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia

This study is ongoing, but not recruiting participants.

Study NCT00003512. Last updated on November 16, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Lymphoma

2	Additional conditions recognized in this trial
		Multiple Myeloma
		Neoplasms, Plasma Cell
		Waldenstrom Macroglobulinemia

3	More general conditions related to this trial
		Blood Protein Disorders
		Cardiovascular Diseases
		Hematologic Diseases
		Hemorrhagic Disorders
		Hemostatic Disorders
		Immune System Diseases
		Immunoproliferative Disorders
		Lymphatic Diseases
		Lymphoproliferative Disorders
		Neoplasms
		Neoplasms by Histologic Type
		Paraproteinemias
		Vascular Diseases

4	Interventions listed in this trial
		antineoplaston A10
		antineoplaston AS2-1

5	Sponsors listed in this trial
		Burzynski Research Institute